Literature DB >> 20308084

Prevalence, patterns, and costs of Chinese medicine use among prostate cancer patients: a population-based study in Taiwan.

Yi-Hsien Lin1, Kuang-Kuo Chen, Jen-Hwey Chiu.   

Abstract

BACKGROUND: Taiwan's National Health Insurance (NHI) is a comprehensive and universal program, providing Western medicine (WM) and Chinese medicine (CM). This study aims to explore CM use among prostate cancer patients in NHI.
METHODS: A cross-section retrospective analysis was conducted using registration and claim data sets from the NHI Research Database. In 2007, 22,352 prostate cancer patients with 265,497 visits of CM and WM ambulatory services were identified. Patient demographics, patterns of therapies, and costs were analyzed.
RESULTS: In 2007, 592 prostate cancer patients (2.6%) had 4141 CM outpatient visits (7.0 on average). The median age was 73.9. The majority (90.5%) of CM users also used WM ambulatory services. About one third of CM outpatient services were provided by private clinics. The most frequently used CM therapies were Chinese herbal medication (93.6%), followed by acupuncture/traumatology manipulative therapies (7.0%). CM accounted for 0.2% expenditure ($87,500) and 1.6% visits of ambulatory services. The average cost per visit for WM was 6.3 times higher than that for CM ($133.6 vs $21).
CONCLUSIONS: The prevalence and costs of insurance-covered CM among prostate cancer patients were low. Most prostate cancer patients did not use insurance-covered CM. The majority of CM users also used WM. CM appeared to play a complementary rather than an alternative role.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308084     DOI: 10.1177/1534735409359073

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  13 in total

1.  Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.

Authors:  Jianguo Bai; Jianfei Wu; Ruifeng Tang; Chao Sun; Junwei Ji; Zhaolin Yin; Guangjun Ma; Wei Yang
Journal:  Invest New Drugs       Date:  2019-04-11       Impact factor: 3.850

2.  Use of Chinese medicine among colorectal cancer patients: a nationwide population-based study.

Authors:  Shiang-Jiun Tsai; Ying-Xu Ruan; Ching-Chih Lee; Moon-Sing Lee; Wen-Yen Chiou; Hon-Yi Lin; Feng-Chun Hsu; Yu-Chieh Su; Ta-Wen Hsu; Shih-Kai Hung
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-01-28

3.  Anti-cancer effect of ursolic acid activates apoptosis through ROCK/PTEN mediated mitochondrial translocation of cofilin-1 in prostate cancer.

Authors:  Wen-Tao Gai; Da-Peng Yu; Xin-Sheng Wang; Pei-Tao Wang
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

Review 4.  Prevalence of the Use of Herbal Medicines among Patients with Cancer: A Systematic Review and Meta-Analysis.

Authors:  John Baptist Asiimwe; Prakash B Nagendrappa; Esther C Atukunda; Mauda M Kamatenesi; Grace Nambozi; Casim U Tolo; Patrick E Ogwang; Ahmed M Sarki
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-17       Impact factor: 2.650

5.  Prescription patterns of herbal medicine for menopausal disorders in major Korean medicine hospitals: a multicenter retrospective study.

Authors:  Hye Won Lee; Tae-Young Choi; Myeong Soo Lee; Ju Ah Lee; Ji Hee Jun; Jiae Choi; Lin Ang; Chang-Hoon Lee; Jin-Moo Lee; Kyoung Sun Park; Dong Chul Kim; Se-Ran Jang; Jeong-Eun Yoo; Dong-Il Kim; Seong-Hee Cho; Seung-Jeong Yang; In Seon Lee; In-Suk Ahn; Dong-Nyung Lee; Chang-Min Choi; Mi-Hwa Song; Eunseop Kim
Journal:  Integr Med Res       Date:  2020-12-04

6.  Coprescription of Chinese Herbal Medicine and Western Medications among Prostate Cancer Patients: A Population-Based Study in Taiwan.

Authors:  Yi-Hsien Lin; Kuang-Kuo Chen; Jen-Hwey Chiu
Journal:  Evid Based Complement Alternat Med       Date:  2011-07-18       Impact factor: 2.629

7.  Use of Chinese medicine by cancer patients: a review of surveys.

Authors:  Bridget Carmady; Caroline A Smith
Journal:  Chin Med       Date:  2011-06-09       Impact factor: 5.455

8.  Distributions of usage and the costs of conventional medicine and traditional chinese medicine for lung cancer patients in taiwan.

Authors:  Yueh-Hsiang Liao; Jaung-Geng Lin; Cheng-Chieh Lin; Tsai-Chung Li
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-16       Impact factor: 2.629

9.  Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan.

Authors:  Yueh-Hsiang Liao; Cheng-Chieh Lin; Tsai-Chung Li; Jaung-Geng Lin
Journal:  BMC Complement Altern Med       Date:  2012-09-05       Impact factor: 3.659

10.  The use of rehabilitation among patients with breast cancer: a retrospective longitudinal cohort study.

Authors:  Yi-Hsien Lin; Po-Jung Pan
Journal:  BMC Health Serv Res       Date:  2012-08-28       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.